60 Degrees Pharmaceuticals, Inc. cash flow to debt ratio of -4.48K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

60 Degrees Pharmaceuticals, Inc.'s free cash flow has decreased 21.24% from $-5.83M last year to $-7.07M, signaling decreasing performance

60 Degrees Pharmaceuticals, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

60 Degrees Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.03 today, signaling strengthened financials

60 Degrees Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

60 Degrees Pharmaceuticals, Inc.'s interest coverage ratio is -1.07K, which means that the company struggles to meet interest obligations, signaling financial risk.

60 Degrees Pharmaceuticals, Inc.'s profit margin has increased (-42.27%) in the last year from -1.31K% to -755.16%, signaling increasing performance

60 Degrees Pharmaceuticals, Inc.'s short-term assets of $4.90M exceed its short-term liabilities of $1.84M

60 Degrees Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

60 Degrees Pharmaceuticals, Inc.'s return on equity of -200.17%, is lower than 15.00%, indicating bad performance

60 Degrees Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

60 Degrees Pharmaceuticals, Inc. has insufficient public price history to evaluate earnings stability.

60 Degrees Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

60 Degrees Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

60 Degrees Pharmaceuticals, Inc.'s yearly earnings has increased -7.28% since last year from $-7.95M to $-7.37M, signaling increasing performance

60 Degrees Pharmaceuticals, Inc.'s yearly revenue has increased 65.49% since last year from $607.57K to $1.01M, signaling increasing performance

ROIC -162.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

60 Degrees Pharmaceuticals, Inc.'s 3-year revenue CAGR of 65.15% is positive, indicating growing revenue over the past 3 years

60 Degrees Pharmaceuticals, Inc. has insufficient public price history to evaluate revenue consistency.

60 Degrees Pharmaceuticals, Inc. has insufficient public price history to evaluate ROE consistency.

60 Degrees Pharmaceuticals, Inc. has insufficient data to evaluate this check.

60 Degrees Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

60 Degrees Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

60 Degrees Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

60 Degrees Pharmaceuticals, Inc. has insufficient data to evaluate this check.

60 Degrees Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

60 Degrees Pharmaceuticals, Inc. has a price-to-book ratio of 0.41x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

60 Degrees Pharmaceuticals, Inc. has a price-to-sales ratio of 1.94x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue